vs
Side-by-side financial comparison of Datadog (DDOG) and PERRIGO Co plc (PRGO). Click either name above to swap in a different company.
PERRIGO Co plc is the larger business by last-quarter revenue ($1.1B vs $953.2M, roughly 1.2× Datadog). Datadog runs the higher net margin — 4.9% vs -127.8%, a 132.7% gap on every dollar of revenue. On growth, Datadog posted the faster year-over-year revenue change (29.2% vs -2.5%). Datadog produced more free cash flow last quarter ($318.2M vs $148.6M). Over the past eight quarters, Datadog's revenue compounded faster (24.9% CAGR vs 1.3%).
Datadog, Inc. is an American company that provides an observability service for cloud-scale applications, providing monitoring of servers, databases, tools, and services, through a SaaS-based data analytics platform. Founded and headquartered in New York City, the company is a publicly traded entity on the Nasdaq stock exchange.
Perrigo Company plc is an American Irish-registered manufacturer of private label over-the-counter pharmaceuticals, and while 70% of Perrigo's net sales are from the U.S. healthcare system, Perrigo is legally headquartered in Ireland for tax purposes, which accounts for 0.60% of net sales. In 2013, Perrigo completed the sixth-largest US corporate tax inversion in history when it reregistered its tax status to Ireland to avoid U.S. corporate taxes. Perrigo maintains its corporate headquarters ...
DDOG vs PRGO — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $953.2M | $1.1B |
| Net Profit | $46.6M | $-1.4B |
| Gross Margin | 80.4% | 32.6% |
| Operating Margin | 1.0% | -116.0% |
| Net Margin | 4.9% | -127.8% |
| Revenue YoY | 29.2% | -2.5% |
| Net Profit YoY | 2.1% | -3093.9% |
| EPS (diluted) | $0.13 | $-10.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $953.2M | $1.1B | ||
| Q3 25 | $885.7M | $1.0B | ||
| Q2 25 | $826.8M | $1.1B | ||
| Q1 25 | $761.6M | $1.0B | ||
| Q4 24 | $737.7M | $1.1B | ||
| Q3 24 | $690.0M | $1.1B | ||
| Q2 24 | $645.3M | $1.1B | ||
| Q1 24 | $611.3M | $1.1B |
| Q4 25 | $46.6M | $-1.4B | ||
| Q3 25 | $33.9M | $7.5M | ||
| Q2 25 | $2.6M | $-8.4M | ||
| Q1 25 | $24.6M | $-6.4M | ||
| Q4 24 | $45.6M | $-44.4M | ||
| Q3 24 | $51.7M | $-21.0M | ||
| Q2 24 | $43.8M | $-108.4M | ||
| Q1 24 | $42.6M | $2.0M |
| Q4 25 | 80.4% | 32.6% | ||
| Q3 25 | 80.1% | 36.1% | ||
| Q2 25 | 79.9% | 34.4% | ||
| Q1 25 | 79.3% | 37.6% | ||
| Q4 24 | 80.5% | 33.9% | ||
| Q3 24 | 80.0% | 37.2% | ||
| Q2 24 | 80.9% | 37.0% | ||
| Q1 24 | 82.0% | 33.1% |
| Q4 25 | 1.0% | -116.0% | ||
| Q3 25 | -0.7% | 7.0% | ||
| Q2 25 | -4.3% | 4.3% | ||
| Q1 25 | -1.6% | 4.5% | ||
| Q4 24 | 1.3% | 10.0% | ||
| Q3 24 | 2.9% | 7.4% | ||
| Q2 24 | 2.0% | -2.5% | ||
| Q1 24 | 2.0% | -5.1% |
| Q4 25 | 4.9% | -127.8% | ||
| Q3 25 | 3.8% | 0.7% | ||
| Q2 25 | 0.3% | -0.8% | ||
| Q1 25 | 3.2% | -0.6% | ||
| Q4 24 | 6.2% | -3.9% | ||
| Q3 24 | 7.5% | -1.9% | ||
| Q2 24 | 6.8% | -10.2% | ||
| Q1 24 | 7.0% | 0.2% |
| Q4 25 | $0.13 | $-10.23 | ||
| Q3 25 | $0.10 | $0.05 | ||
| Q2 25 | $0.01 | $-0.06 | ||
| Q1 25 | $0.07 | $-0.05 | ||
| Q4 24 | $0.14 | $-0.32 | ||
| Q3 24 | $0.14 | $-0.15 | ||
| Q2 24 | $0.12 | $-0.79 | ||
| Q1 24 | $0.12 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $401.3M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $3.7B | $2.9B |
| Total Assets | $6.6B | $8.5B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $401.3M | — | ||
| Q3 25 | $540.6M | $432.1M | ||
| Q2 25 | $489.0M | $454.2M | ||
| Q1 25 | $1.1B | $409.9M | ||
| Q4 24 | $1.2B | $558.8M | ||
| Q3 24 | $337.4M | $1.5B | ||
| Q2 24 | $411.0M | $542.8M | ||
| Q1 24 | $282.2M | $658.5M |
| Q4 25 | $3.7B | $2.9B | ||
| Q3 25 | $3.4B | $4.4B | ||
| Q2 25 | $3.2B | $4.5B | ||
| Q1 25 | $2.9B | $4.4B | ||
| Q4 24 | $2.7B | $4.3B | ||
| Q3 24 | $2.6B | $4.6B | ||
| Q2 24 | $2.4B | $4.5B | ||
| Q1 24 | $2.2B | $4.7B |
| Q4 25 | $6.6B | $8.5B | ||
| Q3 25 | $6.1B | $10.1B | ||
| Q2 25 | $5.8B | $10.1B | ||
| Q1 25 | $6.0B | $9.8B | ||
| Q4 24 | $5.8B | $9.6B | ||
| Q3 24 | $4.6B | $11.2B | ||
| Q2 24 | $4.4B | $10.4B | ||
| Q1 24 | $4.1B | $10.6B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $327.1M | $175.4M |
| Free Cash FlowOCF − Capex | $318.2M | $148.6M |
| FCF MarginFCF / Revenue | 33.4% | 13.4% |
| Capex IntensityCapex / Revenue | 0.9% | 2.4% |
| Cash ConversionOCF / Net Profit | 7.02× | — |
| TTM Free Cash FlowTrailing 4 quarters | $1.0B | $145.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $327.1M | $175.4M | ||
| Q3 25 | $251.5M | $51.7M | ||
| Q2 25 | $200.1M | $75.9M | ||
| Q1 25 | $271.5M | $-64.5M | ||
| Q4 24 | $265.2M | $312.6M | ||
| Q3 24 | $228.7M | $42.2M | ||
| Q2 24 | $164.4M | $9.5M | ||
| Q1 24 | $212.3M | $-1.4M |
| Q4 25 | $318.2M | $148.6M | ||
| Q3 25 | $234.7M | $29.8M | ||
| Q2 25 | $184.9M | $56.7M | ||
| Q1 25 | $262.8M | $-90.0M | ||
| Q4 24 | $257.5M | $274.9M | ||
| Q3 24 | $220.3M | $15.1M | ||
| Q2 24 | $160.0M | $-18.9M | ||
| Q1 24 | $198.1M | $-26.5M |
| Q4 25 | 33.4% | 13.4% | ||
| Q3 25 | 26.5% | 2.9% | ||
| Q2 25 | 22.4% | 5.4% | ||
| Q1 25 | 34.5% | -8.6% | ||
| Q4 24 | 34.9% | 24.2% | ||
| Q3 24 | 31.9% | 1.4% | ||
| Q2 24 | 24.8% | -1.8% | ||
| Q1 24 | 32.4% | -2.4% |
| Q4 25 | 0.9% | 2.4% | ||
| Q3 25 | 1.9% | 2.1% | ||
| Q2 25 | 1.8% | 1.8% | ||
| Q1 25 | 1.1% | 2.4% | ||
| Q4 24 | 1.1% | 3.3% | ||
| Q3 24 | 1.2% | 2.5% | ||
| Q2 24 | 0.7% | 2.7% | ||
| Q1 24 | 2.3% | 2.3% |
| Q4 25 | 7.02× | — | ||
| Q3 25 | 7.42× | 6.89× | ||
| Q2 25 | 75.58× | — | ||
| Q1 25 | 11.02× | — | ||
| Q4 24 | 5.82× | — | ||
| Q3 24 | 4.42× | — | ||
| Q2 24 | 3.75× | — | ||
| Q1 24 | 4.98× | -0.70× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DDOG
| North America | $678.7M | 71% |
| International | $274.5M | 29% |
PRGO
| Consumer Self Care Americas | $697.0M | 63% |
| Digestive Health | $123.9M | 11% |
| Nutrition | $108.3M | 10% |
| Healthy Lifestyle | $94.8M | 9% |
| Pain And Sleep Aids | $87.1M | 8% |
